AptarGroup beats; Q4 EPS guide implies ~17% rebound on Pharma strength

 

AptarGroup beats Q3 estimates with non-GAAP EPS $1.52 (-6% YoY) on $1.0B revenue (+6% YoY), Q4 EPS guide implies ~17% rebound on Pharma strength

• Q4 2026 adjusted EPS guidance of $1.39–$1.47 implies ~17% YoY growth as Pharma margins expand post-destocking.
• Pharma core sales grew 8% excluding emergency medicine, with 36.4% adjusted EBITDA margin in the quarter.
• Emergency medicine destocking still weighs on results, but the headwind is expected to lap after Q4 2026.
• Beauty and Closures posted strong core growth but saw margin pressure, especially in Beauty North America.
• Deconsolidation of Russian subsidiary in Q3 2026 drove $60M loss and $0.94 GAAP EPS charge, excluded from adjusted results.
• Sales were up 6% to $1.02B, alongside reported Q3 2026 revenue of $1.0B (+6% YoY).
• AptarGroup raised its quarterly dividend about 4% to $0.50 per share, payable December 3, 2026.
• Dividend record date set for November 12, 2026 for investors eligible to receive the $0.50 payment.
• Management reiterated Pharma’s 7–11% long-term growth corridor, citing a robust diversified pipeline.
• Injectables and consumer healthcare remain standout growth drivers, helped by GLP-1, biologics and Annex 1.
• New CEO prioritizes execution and profitability, targeting a multi-year turnaround in North American Beauty operations.
• Company maintained a strong balance sheet, generated $198 million free cash flow and stepped up capital returns.
• Main investor debate focuses on durability of Pharma growth versus timing and success of the Beauty margin fix.
• Main concern is persistent underperformance and execution risk in North American Beauty margins despite healthy demand.
• Overall mixed quarter, with strong underlying Pharma growth offset by emergency medicine destocking and Beauty margin pressure.

https://finviz.com/stock?t=ATR&p=d